Wegovy Medicare Part D Rules: What’s Covered, What’s Not, And How To Navigate Costs
If you've ever tried to make sense of Medicare Part D coverage for Wegovy, you've probably run into the same frustrating sentence over and over: "Medicare doesn't cover weight loss drugs." That's mostly true. But it's not the whole story anymore.
Since March 2024, Wegovy (semaglutide 2.4 mg) has an FDA-approved indication to reduce major cardiovascular events in certain higher-risk adults. That single regulatory detail created a real (and confusing) coverage pathway under Part D for some people, while most others still face a hard "not covered" for weight management alone.
In this guide, we'll walk through the current Wegovy Medicare Part D rules, when coverage is possible, how to check your plan, what costs can look like, and what to do if you hit a denial, without sugarcoating it or burying you in insurance jargon.
How Medicare Part D Treats Wegovy (And Why Coverage Is Limited)
Medicare Part D is the prescription drug benefit that typically covers "self-administered" medications you pick up at the pharmacy, including many injectables. Wegovy falls into that general category.
But Part D doesn't just ask, "Is this a prescription drug?" It also asks, "Is this drug being used for an indication Medicare is allowed to cover?" That second question is where Wegovy gets complicated.
Wegovy's FDA Indications: Weight Loss vs Cardiovascular Risk Reduction
Wegovy has two key FDA-labeled uses that matter for Medicare coverage discussions:
First, chronic weight management. Wegovy is approved for adults with obesity (body mass index, BMI, of 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related condition.
Second, cardiovascular risk reduction. In March 2024, the FDA approved Wegovy to reduce the risk of major adverse cardiovascular events (for example, heart attack, stroke, cardiovascular death) in adults who have overweight/obesity and established cardiovascular disease.
That second indication is the pivot point. It's not "weight loss as the goal." It's cardiovascular event reduction in a higher-risk group, with weight status as part of the eligibility criteria.
The Medicare Rule: Weight Loss Drugs Are Generally Excluded
Here's the core rule: Medicare is generally prohibited by statute from covering drugs when they're prescribed solely for weight loss.
So even if Wegovy is clinically appropriate for weight management, and even if it's helping blood pressure, fatty liver markers, or sleep apnea symptoms along the way, Part D plans usually cannot cover Wegovy when the documented indication is "weight loss" or "weight management."
That's why people on Medicare often see a denial even when their clinician agrees the medication is medically necessary. It's not always a plan "preference." In many cases, it's a coverage category problem: weight loss is an excluded benefit.
The important nuance is that Part D can cover the same drug if it's prescribed for a non-excluded, FDA-labeled indication and your documentation matches that indication. Wegovy's cardiovascular approval opened that door for a subset of beneficiaries.
When Wegovy May Be Covered Under Part D
Even with the March 2024 FDA update, coverage is not automatic. In practice, Part D coverage tends to be narrow, documentation-heavy, and plan-specific.
Coverage Pathway: FDA-Labeled Cardiovascular Indication And Diagnosed ASCVD
The clearest pathway is the FDA-labeled cardiovascular indication.
In plain English, Part D coverage is most plausible when all of the following are true:
You have established atherosclerotic cardiovascular disease (ASCVD). That typically means a documented history of conditions like prior heart attack (myocardial infarction), prior stroke, symptomatic peripheral artery disease, or other clearly diagnosed ASCVD.
You meet the weight criterion (overweight or obesity).
Your prescriber documents that Wegovy is being used to reduce cardiovascular risk consistent with the FDA label.
Some analyses have estimated that roughly 3.6 million Medicare beneficiaries (around 7%) may meet criteria that could make them eligible under this cardiovascular pathway, though actual coverage still depends on whether a specific plan has added Wegovy and what restrictions they apply.
We're also seeing plans evolve. Some plans added coverage after the FDA approval, and broader adoption has been expected to expand over time (for example, during 2025 plan-year updates and beyond). But "more plans" still doesn't mean "most people," especially if the diagnosis doesn't match the label.
What Typically Does Not Qualify (Including Prediabetes And "Weight Management Only")
This is where many people get stuck.
In most cases, Part D coverage does not apply if the documented reason for prescribing Wegovy is any of the following:
Prediabetes alone. Prediabetes raises cardiometabolic risk, but it is not the same as established ASCVD, and it is not an FDA-labeled Wegovy indication that sidesteps the statutory weight-loss exclusion.
Overweight or obesity without established cardiovascular disease. Even severe obesity by itself (including BMI above 35) typically doesn't satisfy Part D's requirement to avoid the "weight loss drug" exclusion.
"Weight management only," even when there are comorbidities. Clinically, we might consider multiple obesity-related conditions when deciding on therapy. But for Medicare coverage, the category and the documented indication are what drive the decision.
If you're reading this and thinking, "But obesity is a disease, why doesn't that count?" We agree it's a disease. The challenge is that Medicare's coverage statutes haven't fully caught up with modern obesity medicine, which is why coverage remains limited and inconsistent.
There are also pilots and proposals floating around (including limited demonstrations that may involve obesity plus cardiovascular conditions for a subset of beneficiaries), but those do not equal broad Part D coverage for anti-obesity medications.
How To Check If Your Part D Plan Covers Wegovy
We can't reliably guess coverage based on the plan's brand name or what your neighbor's plan did last year. The only dependable way is to check your specific plan's current formulary and utilization rules.
Formulary Lookups, Prior Authorization, Step Therapy, And Quantity Limits
Start with a formulary lookup.
Most Part D plans publish an online formulary (their covered drug list). When you search "Wegovy," pay attention to two things:
- Is it listed at all? Some plans still don't list Wegovy.
- If it is listed, what restrictions apply? Common ones include:
Prior authorization (PA). This means the plan requires your clinician to submit documentation showing you meet the plan's criteria before the pharmacy can dispense it.
Step therapy (ST). This means the plan may require you to try other covered therapies first (or document why they're not appropriate).
Quantity limits (QL). This sets limits on how much can be dispensed in a given time period, which can matter during dose escalation.
Also check tier placement. Wegovy is frequently placed on a higher tier (often "specialty"), which can increase coinsurance.
The Documents Your Prescriber May Need To Submit
When PA is required, the plan typically wants proof that your situation matches the FDA-labeled cardiovascular indication and the plan's internal criteria.
While the exact PA form varies, the common documentation requests include:
A clear diagnosis of established ASCVD in your chart, often supported by problem list entries and/or clinical documentation (for example, hospital discharge summaries, cardiology notes, imaging reports).
Your BMI, usually with a current height and weight.
A statement of medical necessity aligned with the FDA label, emphasizing cardiovascular risk reduction (not weight loss as the primary documented purpose).
Medication history, which may be relevant if the plan applies step therapy.
If your clinician is submitting a PA, it can help to ask them (politely) what the plan is asking for so you can ensure the relevant records are available. Many denials are not about the medicine itself, they're about missing or mismatched documentation.
What Wegovy Can Cost With Medicare Part D (And Why Out-Of-Pocket Varies)
Even when Wegovy is covered, cost is often the next shock. Part D out-of-pocket (OOP) costs can vary dramatically based on deductible, tier, coinsurance, and where you are in the year.
Deductible, Copays/Coinsurance, And Tier Placement Basics
Here's the basic flow of how Part D cost sharing tends to show up at the pharmacy counter:
Deductible. Some plans require you to pay a deductible before coverage kicks in. For 2026, the Part D deductible can be as high as $615 (plans can choose a lower deductible or none).
Copay vs coinsurance. A copay is a fixed amount (for example, $40). Coinsurance is a percentage of the drug's cost (for example, 25% to 33%). High-cost drugs placed on specialty tiers are often coinsurance-based.
Tier placement. Higher tiers generally mean higher cost sharing and more restrictions.
Because Wegovy's list price is high, coinsurance can translate into hundreds of dollars per month in some plans, especially early in the year before you hit any cost-sharing protections.
You may see examples like $325 to $430 per month in certain scenarios, but we have to emphasize this: your number could be much lower or much higher depending on your plan design and the timing in the calendar year.
The Annual Out-Of-Pocket Maximum And What It Means For High-Cost Drugs
One important change in recent years is the introduction of a Part D annual out-of-pocket maximum (a cap). For people on high-cost medications, this can be meaningful.
For 2026, the out-of-pocket cap has been described as $2,100. The practical takeaway is that once your "true out-of-pocket" spending reaches the cap, you should not keep paying unlimited amounts for covered Part D drugs the rest of that year.
Two details matter here:
First, the cap applies only if the drug is covered. If Wegovy is denied as a non-covered weight loss drug, you don't get the benefit of the cap.
Second, your out-of-pocket pathway can still feel steep at the beginning of the year. A deductible plus coinsurance can create large early-month bills, even if costs later stabilize after you approach the cap.
If you're budgeting, it's smart to model best-case and worst-case: what you'd pay in month one, and what your maximum annual spend could be if it's covered and you continue therapy.
Exceptions, Appeals, And Switching Plans: Your Main Levers
If you're denied, you're not necessarily stuck. Medicare has a formal process, and you also have strategic timing tools (like Open Enrollment) that can be even more powerful than an appeal.
Requesting A Coverage Determination Or Formulary Exception
The starting point is usually a coverage determination.
If Wegovy is on the formulary but you're denied at the pharmacy due to PA not being met, you and your prescriber can pursue the plan's PA process or request a coverage determination explaining why the criteria are met.
If Wegovy is not on the formulary at all, your clinician can request a formulary exception. In this request, they typically need to explain why alternatives on the formulary would be less effective or would cause adverse effects.
One reality check: if the plan denies because they believe the request falls under the statutory exclusion (weight loss), an exception request often fails unless you truly meet the cardiovascular indication with established ASCVD and the documentation supports it.
Appeals Timeline, Supporting Evidence, And Common Denial Reasons
If the plan denies coverage, you can appeal. Appeals generally need to be filed within a defined window (commonly within 60 days of the denial notice).
Common denial reasons we see:
Indication mismatch. The plan interprets the request as weight loss treatment rather than cardiovascular risk reduction.
No documented ASCVD. Risk factors alone (high blood pressure, high cholesterol, prediabetes, family history) don't equal established ASCVD in the way the PA criteria often define it.
Missing documentation. The diagnosis exists, but the records weren't attached or weren't clear.
Dose or quantity issues. The plan flags the requested dose or timing as inconsistent with their quantity limits.
What tends to strengthen an appeal is clear, label-aligned documentation: the specific ASCVD diagnosis, relevant medical history, BMI, and a straightforward rationale that the medication is being used for the FDA-approved cardiovascular indication.
Comparing Plans During Open Enrollment And Special Enrollment Periods
Sometimes the most effective move is not an appeal, it's a plan comparison.
During Medicare Open Enrollment (October through December), you can compare Part D and Medicare Advantage plans, checking:
Whether Wegovy is listed on the formulary for the upcoming year
What tier it's on
What PA or step therapy requirements apply
What your estimated annual out-of-pocket cost would be
If you qualify for a Special Enrollment Period (SEP) due to certain life events or plan changes, you may be able to switch outside of Open Enrollment.
We can't choose your plan for you, but we can say this: for expensive drugs, the plan design matters as much as the drug coverage itself. Two plans can both "cover Wegovy" and still leave you with very different real-world costs.
If Wegovy Isn’t Covered: Practical Alternatives To Discuss With Your Clinician
If your Part D plan won't cover Wegovy, it's easy to feel like the door has slammed shut. In reality, there are often other medically reasonable paths, depending on your diagnoses, your goals, and what you can tolerate.
Covered Options That May Address Cardiometabolic Risk
The right alternative depends on what we're treating.
If you have type 2 diabetes, some GLP-1 receptor agonists may be covered under Part D when used for diabetes management (for example, semaglutide products labeled for diabetes rather than obesity). That doesn't mean you should switch labels casually, your clinician has to prescribe according to your diagnosis and the FDA indication.
If your main issue is cardiovascular risk, your clinician may also focus on therapies Medicare commonly covers that reduce risk in proven ways: statins and other lipid-lowering therapies, blood pressure medications, smoking cessation support, and diabetes control when applicable.
And don't overlook Part B benefits. Medicare Part B can cover certain preventive and behavioral health services, including intensive behavioral therapy for obesity in qualifying settings. Coverage and logistics vary, but it's worth asking about.
Non-Drug Strategies That Improve Tolerability And Adherence On GLP-1 Therapy
Even when we can't solve coverage overnight, we can often improve the day-to-day experience of GLP-1 therapy. Adherence (staying on a medication long enough to benefit) is heavily influenced by side effects, especially gastrointestinal ones.
Common GLP-1 side effects include nausea, constipation, reflux, bloating, and a "stuck" feeling after eating because gastric emptying is slowed.
Non-drug strategies that are often discussed in clinical practice include:
Meal sizing and timing. Smaller portions, slower eating, and avoiding high-fat meals can reduce nausea for many people.
Protein-first structure. When appetite is low, prioritizing protein can help preserve lean mass, which matters for metabolic rate and strength during weight loss.
Hydration plus electrolytes. Constipation and fatigue often worsen when fluid intake drops.
Fiber strategies that don't backfire. Some people do well with gradual psyllium increases: others get more bloating if they escalate too fast.
Gut-tolerant nutrition planning. For those with IBS tendencies or sensitive stomachs, lower-FODMAP approaches can reduce gas and distention while you're adapting.
Digestive discomfort is one of the most common reasons people struggle with GLP-1 medications. Targeted nutrition support can make a real difference in tolerability. Casa de Sante's physician-formulated digestive enzymes, synbiotics, and motility support supplements are designed specifically for sensitive stomachs on GLP-1 therapy. See what's available at casadesante.com.
Conclusion
The headline rule is still true: Medicare Part D generally does not cover Wegovy for weight loss alone. The newer, more important nuance is that Wegovy may be covered when it's prescribed for its FDA-approved cardiovascular risk reduction indication in adults with overweight/obesity and established ASCVD.
So our practical approach is this: verify formulary status, anticipate prior authorization, make sure the documented indication matches the FDA label, and if you're denied, decide quickly whether an appeal is realistic or whether plan shopping during Open Enrollment is the smarter lever.
Above all, we want you to leave this process with clarity instead of confusion. Coverage rules can feel impersonal, but your health goals aren't. With the right documentation and the right plan, some people can access Wegovy under Part D, and when they can't, there are still evidence-based options worth discussing with a clinician who takes obesity and cardiometabolic risk seriously.
This article is for educational purposes only and is not medical advice. Always consult your healthcare provider before making changes to your treatment plan.
Frequently Asked Questions About Wegovy Medicare Part D Rules
Do Wegovy Medicare Part D rules cover Wegovy for weight loss?
Usually no. Under current Wegovy Medicare Part D rules, drugs prescribed solely for weight loss are generally excluded by statute. Even if Wegovy helps blood pressure or other obesity-related issues, Part D typically denies coverage when the documented indication is “weight management” rather than a non-excluded, FDA-labeled use.
When can Medicare Part D cover Wegovy after the March 2024 FDA update?
Coverage is most plausible when Wegovy is prescribed for its FDA-approved cardiovascular risk reduction indication. That generally means you have overweight/obesity plus established atherosclerotic cardiovascular disease (ASCVD), such as a prior heart attack, stroke, or symptomatic peripheral artery disease, and your prescriber documents CV risk reduction—not weight loss.
Does prediabetes qualify for Wegovy coverage under Medicare Part D?
Prediabetes alone typically doesn’t qualify under Wegovy Medicare Part D rules. Plans usually require established ASCVD to align with Wegovy’s cardiovascular label and avoid the “weight loss drug” exclusion. Risk factors like prediabetes, high cholesterol, or hypertension may increase risk, but they’re not the same as documented ASCVD.
How do I check if my Part D plan covers Wegovy, and what restrictions are common?
Check your plan’s online formulary and look up “Wegovy.” If it’s listed, review restrictions such as prior authorization (PA), step therapy (ST), and quantity limits (QL), plus the tier (often specialty). Coverage can vary widely by plan and year, so verifying your exact plan is essential.
What documents are usually needed for prior authorization for Wegovy under Part D?
Plans commonly request proof of established ASCVD (e.g., cardiology notes, hospital records, problem list), a current BMI from height/weight, and a medical-necessity statement that matches the FDA cardiovascular indication. Many denials happen due to missing or mismatched documentation rather than the drug itself.
If Wegovy isn’t covered, what are practical alternatives to discuss with my clinician?
If Wegovy is denied, ask about covered options tied to your diagnosis—e.g., GLP-1 medicines indicated for type 2 diabetes if you have diabetes, plus proven cardiovascular risk reducers like statins and blood pressure therapy. Also ask about Medicare Part B intensive behavioral therapy for obesity, if you qualify.
